Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allergovac Poliplus Safety and Tolerability in Allergic Rhinoconjunctivitis
NCT02849249Phase 1Completed
- Sponsor
- ROXALL Medizin GmbH
- Start
- Sep 2015
- Primary completion
- Jun 2016
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of allergovac poliplus in allergic rhinoconjunctivitis (ARC) (2 arms), sponsored by ROXALL Medizin GmbH. Primary endpoint: Number and severity of adverse reactions. Started Sep 2015; status: completed.
02
Drugs
allergovac poliplus
03
Conditions
allergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on NCT02849249.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02849249.